EUVIMEDEUVIMED entdecken
Crossref

Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies

Hui Huang, Gang Zhao, Tierun Wang, Yi You, Tian Zhang, Xi Chen, Jie Dong, Lei Gong, Xiaobin Shang, Fuliang Cao, Peng Tang, Hongjing Jiang und 4 weitere

Cancer Letters · 2024-10 · 601 · 217178

DOI: 10.1016/j.canlet.2024.217178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2024-10. Verfasst von Hui Huang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laborator…. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Tertiary Lymphoid Structures, Esophageal Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tertiary lymphoid structures (TLSs) were associated with survival in esophageal squamous cell carcinoma (ESCC) undergoing surgery alone (SA). However, their clinical relevance in neoadjuvant therapies remains less known. Here, we firstly investigated the presence, maturation and spatial distribution of TLSs in 359 ESCC patients receiving neoadjuvant chemotherapy (NCT), neoadjuvant immunotherapy (NCI), neoadjuvant chemoradiotherapy (NCRT) or SA. We found mature TLS (MTLS) was an independent prognostic factor in ESCC. NCI group had the lowest immature TLS cases. NCRT group had the lowest MTLSs. MTLSs mostly located in stromal and normal compartments; these MTLSs were positively correlated with neoadjuvant therapy outcomes. NCI group displayed the highest T cells within 150 μm proximity of TLSs among the four groups. Most T cells were dispersed up to more than 150 μm from TLSs, while B cells remained concentrated within TLSs. Innate lymphoid cells and follicular dendritic cells infiltrated and connected with survival differently in NCRT and NCI groups compared with SA group. The novel PD-L1 combined positive score, NCPS, was positively connected with MTLSs and neoadjuvant therapy efficacy. ScRNA-seq analysis revealed TLS+ tumors had increased plasma cells, B cells, Th17, Tfh and Th1, and elevated exhausted CD8+ T cells that highly expressed checkpoint molecules and granzymes. Conclusively, MTLSs favored treatment outcome in ESCC patients receiving multiple neoadjuvant therapies. The spatial distribution of MTLSs was associated with multiregional immune status modified by the neoadjuvant therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyEsophageal Squamous Cell CarcinomaTertiary Lymphoid StructuresEsophageal NeoplasmsHumansFemaleMaleMiddle AgedAgedPrognosisImmunotherapyTumor MicroenvironmentLymphocytes, Tumor-Infiltrating

Stichwörter der Autor:innen

Esophageal squamous cell carcinomaImmunotherapyNeoadjuvant therapyRadiotherapyTertiary lymphoid structure

Autor:innen und Institutionen

  • Department of Radiation Oncology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center…
  • Department of Pathology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Canc…
  • Department of Nutrition Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin's Clinical Research Cent…
  • Department of Esophageal Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center…
  • Department of Endoscopy Diagnosis and Therapy, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Re…
  • Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin's Clinical Research Center for…

Zitieren

APA

Huang, H., Zhao, G., Wang, T., You, Y., Zhang, T., Chen, X., Dong, J., Gong, L., Shang, X., Cao, F., Tang, P., Jiang, H., Wang, P., Pang, Q., Yan, C., & Zhang, W. (2024). Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies. Cancer Letters, 601, 217178. https://doi.org/10.1016/j.canlet.2024.217178

Vancouver

Huang H, Zhao G, Wang T, You Y, Zhang T, Chen X, et al. Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies. Cancer Letters. 2024;601:217178. doi:10.1016/j.canlet.2024.217178

BibTeX
@article{Huang2024,
  author = {Huang, Hui and Zhao, Gang and Wang, Tierun and You, Yi and Zhang, Tian and Chen, Xi and Dong, Jie and Gong, Lei and Shang, Xiaobin and Cao, Fuliang and Tang, Peng and Jiang, Hongjing and Wang, Ping and Pang, Qingsong and Yan, Cihui and Zhang, Wencheng},
  title = {Survival benefit and spatial properties of tertiary lymphoid structures in esophageal squamous cell carcinoma with neoadjuvant therapies},
  journal = {Cancer Letters},
  year = {2024},
  volume = {601},
  pages = {217178},
  doi = {10.1016/j.canlet.2024.217178}
}
Kostenlos starten →